We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need.
Our lead asset, Seladelpar, is a potent, selective, orally active PPARδ agonist currently in development for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis (PBC) and for the treatment of patients with nonalcoholic steatohepatitis (NASH). We have initiated the seladelpar Phase 3 registration study for the treatment of PBC and we are also conducting a Phase 2b proof-of-concept study for the treatment of NASH.
Seladelpar has received orphan drug designation for PBC by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), and also has Breakthrough Therapy Designation from the FDA and PRIority MEdicines (PRIME) status from the EMA for the treatment of PBC.
Our pipeline also includes additional investigational products and lead candidates for liver and other chronic diseases.